Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA's October 2026 approval of pirtobrutinib for treatment-naive CLL has added yet another option to an already crowded field — and raised tough new questions about sequencing and resistance. Expert Dr. Mary Ann Anderson says there's no one-size-fits-all answer: the right choice depends on patient comorbidities, genetics, and long-term treatment goals. Emerging BTK degraders and bispecific antibodies are next on the horizon.
The FDA's October 2026 approval of pirtobrutinib (Jaypirca) for previously untreated chronic lymphocytic leukemia (CLL) has expanded an already rich treatment landscape — and with it, the complexity of clinical decision-making. Hematologist Dr. Mary Ann Anderson notes that while patients are fortunate to have so many effective options, clinicians now face a wide array of choices: continuous vs. time-limited therapy, doublets vs. triplets, BTK inhibitors vs. BCL-2 inhibitors, and fixed-duration vs. MRD-guided approaches.
The phase 3 CLL17 trial — comparing continuous ibrutinib against venetoclax-based time-limited regimens — offers some early clarity: at roughly 3 years of follow-up, progression-free survival appears equivalent across arms, even in patients with high-risk genetic features. Still, resistance mechanisms remain poorly understood, particularly when venetoclax is used in combination with different BTK inhibitor partners. Anderson also flags a key sequencing caveat: unlike covalent BTK inhibitors, there are no data showing that pirtobrutinib failure can be rescued by earlier-generation agents.
Key Takeaways
Why it matters: With treatment horizons spanning 10–20 years, the sequencing decisions made at first-line therapy can significantly shape a patient's long-term outcomes. Individualized, patient-centered conversations are now essential — not optional.
